RxDoctor Payments Data

Thomas Beamer, MD

Family Medicine · Carpinteria, CANPI 1538273933

Payments from drug & device makers

$2,586in general payments, 2019–2025

Across 154 payments — averaging $16.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$555
  • AstraZeneca$475
  • Lilly USA, LLC$239
  • Amgen$188
  • Boehringer Ingelheim$165
  • Johnson & Johnson$154
  • plus $811 from 15 others

What the payments were for

  • Food & beverage$2,56299%
  • Education$241%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,586 in reported general payments places this provider in the 85th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$222,757
Medicare patients
310
Services billed
20,209

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol181$163,960
JardianceEmpagliflozin140$143,623
OzempicSemaglutide107$131,308
EliquisApixaban143$102,806
TrulicityDulaglutide75$83,355
XareltoRivaroxaban47$49,191
MyrbetriqMirabegron54$36,111
Repatha SyringeEvolocumab31$16,524
Mesalamine14$14,592
LinzessLinaclotide16$13,281
RybelsusSemaglutide12$12,623
Rosuvastatin Calcium464$9,815
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen257$8,059
Fluvastatin ErFluvastatin Sodium27$7,416
OxycontinOxycodone Hcl11$6,455

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$475$163,960181 claims
Novo NordiskOzempic, Rybelsus$555$143,931119 claims
Boehringer IngelheimJardiance$165$143,623140 claims
PfizerEliquis$152$102,806143 claims
Lilly USA, LLCTrulicity$239$83,35575 claims
Johnson & JohnsonXarelto$154$49,19147 claims
AbbVieLinzess$67$13,28116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 10,533 family medicine providers in California.

Other family medicine in Carpinteria

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →